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Pathological gambling [PG—now termed
“gambling disorder” in DSM-5 (APA,
2013; Petry et al., 2013)] is character-
ized by maladaptive patterns of gam-
bling that are associated with significant
impairments in functioning. Over the past
decade, significant advances have been
made in understanding the pathophysi-
ology of PG (Potenza, 2013). Similarities
between PG and substance-use disorders
(Petry, 2006; Potenza, 2006; Leeman and
Potenza, 2012) prompted the reclassifi-
cation of PG in DSM-5 as an addictive
disorder (rather than an impulse-control
disorder, as was the case in DSM-IV).
Multiple neurotransmitter systems have
been implicated in PG including seroton-
ergic, noradrenergic, dopaminergic, opioi-
dergic, and glutamatergic (Potenza, 2013).
An understanding of these systems as
they relate to PG is important clini-
cally for drug development as presently
there are no FDA-approved medications
with indications for PG. Dopamine has
long been implicated in substance addic-
tions and early articles postulated a sim-
ilarly important role for dopamine in
PG (Potenza, 2001). However, a precise
role for dopamine in PG remains unclear.
Studies of cerebrospinal fluid samples
indicated low levels of dopamine and high
levels of dopamine metabolites in PG, rais-
ing the possibility of increased dopamine
turnover (Bergh et al., 1997). However,
medications that target dopamine func-
tion have not demonstrated clinical effects
in PG. For example, medications that
block dopamine D2-like receptor function
(e.g., olanzapine) have shown negative
results in small, randomized clinical trials
(Fong et al., 2008; McElroy et al., 2008).
Furthermore, a D2-like dopamine recep-
tor antagonist widely used in the treatment
of psychotic disorders (haloperidol) was
found to increase gambling-related moti-
vations and behaviors in individuals with
PG (Zack and Poulos, 2007). However,
administration of the pro-dopaminergic
(and pro-adrenergic) drug amphetamine
also led to increased gambling-related
thoughts and behaviors in PG (Zack and
Poulos, 2004).
Recent imaging studies have begun
to use radioligands and positron-
emission tomography to investigate
dopamine function in PG. In contrast
to findings in cocaine dependence in
which between-group differences were
observed in [11C]raclopride-binding
in the striatum, similar levels were
observed in PG and comparison sub-
jects by two investigative groups (Linnet
et al., 2010, 2011; Clark et al., 2012).
Similarly, no between-group difference
between PG and comparison subjects
was observed using [11C]raclopride or
the D3-preferring agonist-radioligand
[11C]-(+)-propyl-hexahydro-naphtho-
oxazin (PHNO) (Boileau et al., 2013).
However, in these studies, relation-
ships with mood-related or generalized
impulsivity, disadvantageous decision-
making or problem-gambling severity
were reported, suggesting that dopamine
function may relate to specific aspects
of PG (Potenza and Brody, 2013). These
findings are consistent with the idea that
PG represents a heterogeneous condition
and that identifying biologically relevant
individual differences or subgroups may
help advance treatment development or
the appropriate targeting of therapeutic
interventions.
A now well-documented association
between dopamine and PG exists in
Parkinson’s disease (PD) (Leeman and
Potenza, 2011). Specifically, dopamine
agonists (e.g., pramipexole, ropinirole)
have been associated with PG and exces-
sive or problematic behaviors in other
domains (relating to sex, eating, and shop-
ping) in individuals with PD (Weintraub
et al., 2010). Furthermore, levodopa dos-
ing has also been associated with these
conditions in PD (Weintraub et al., 2010).
However, factors seemingly unrelated to
dopamine (e.g., age of PD onset, marital
status and geographic location) have also
been associated with these conditions in
PD (Voon et al., 2006; Weintraub et al.,
2006, 2010; Potenza et al., 2007), high-
lighting the complicated etiologies of these
disorders. Nonetheless, in a study using
[11C]raclopride, individuals with PD and
PG as compared to those with PD alone
demonstrated in the ventral (but not dor-
sal) striatum diminished D2-like binding
at baseline and greater [11C]raclopride
displacement during a gambling/decision-
making task (suggesting greater dopamine
release in the PG group during task perfor-
mance) (Steeves et al., 2009). These find-
ings are reminiscent of those suggesting
blunted levodopa-induced displacement
of [11C]raclopride in the ventral but not
dorsal striatum in PD subjects who self-
administer dopamine-replacement thera-
pies to excess (as compared to those who
do not) (Evans et al., 2006). As other find-
ings have identified in association with
behavioral addictions in PD (vs. those
with PD alone) relatively reduced signal
in the ventral striatum at baseline and
during risk-taking (Rao et al., 2010), a
question arises as to whether dopamine
might relate to these processes in PD.
Similar questions exist about the relatively
blunted ventral striatal activation seen in
non-PD PG in non-ligand-based imaging
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during simulated gambling (Reuter et al.,
2005) and monetary reward processing
(Balodis et al., 2012a; Choi et al., 2012).
Although multiple studies have found
blunted ventral striatal activation during
the monetary-reward-anticipation phase
(particularly during the performance of
Monetary Incentive Delay tasks) across
multiple addictive disorders [e.g., alcohol-
use (Wrase et al., 2007; Beck et al., 2009)
and tobacco-use (Peters et al., 2011) dis-
orders] and other conditions character-
ized by impaired impulse control [e.g.,
binge-eating disorder (Balodis et al., 2013,
in press)], other studies have found rela-
tively increased ventral striatal activation
during reward processing in individuals
with PG and those with other addic-
tions (Hommer et al., 2011; van Holst
et al., 2012a), further raising questions
about how striatal function contributes
precisely to PG and addictions and how
dopamine may be involved in these pro-
cesses (Balodis et al., 2012b; Leyton and
Vezina, 2012; van Holst et al., 2012b).
Although much of the radioligand-
related data described above investigate
D2/D3 receptor function, other dopamine
receptors warrant consideration in PG.
For example, on a rodent slot-machine
task, the D2-like receptor agonist quin-
pirole enhanced erroneous expectations
of reward on near-miss trials, and this
effect was attenuated by a selective D4
(but not D3 or D2) dopamine receptor
antagonist (Cocker et al., 2013). These
preclinical findings complement human
studies that suggest a role for the D4
dopamine receptor in gambling behaviors.
For example, allelic variation at the gene
coding for the D4 dopamine receptor has
been associated with differential responses
to levodopa-related increases in gam-
bling behaviors (Eisenegger et al., 2010).
These findings complement a larger liter-
ature linking the D4 dopamine receptor
to impulsivity-related constructs and dis-
orders like attention-deficit/hyperactivity
disorder, albeit somewhat inconsistently
(Ebstein et al., 1996; Gelernter et al.,
1997; DiMaio et al., 2003). As preclini-
cal (Fairbanks et al., 2012) and human
(Sheese et al., 2012) data suggest gene-
by-environment interactions involving the
gene encoding the D4 dopamine receptor
and aspects of impulsive or poorly con-
trolled behaviors, further research should
examine a role for the D4 dopamine recep-
tor in PG, particularly in studies employ-
ing careful assessments of environmental
and genetic factors. Although several D4-
preferring/selective agonist compounds
(e.g., PD-168,077 and CP-226,269) have
been used in preclinical studies to study
D4 receptors, additional research is needed
to study human D4 dopamine receptors as
might be accomplished through positron-
emission-tomography studies—this repre-
sents an important line of future research
(Bernaerts and Tirelli, 2003; Tarazi et al.,
2004; Basso et al., 2005). Additionally, as
the D1 dopamine receptor has been impli-
cated in addictions like cocaine depen-
dence (Martinez et al., 2009), a role for the
D1 dopaminergic system in PG warrants
exploration.
The above findings indicate that
how dopaminergic function may con-
tribute to PG and other addictions is
currently at an early stage of understand-
ing. Current data suggest that individual
variability in dopamine function may
obscure differences between PG and
non-PG populations, with arguably the
strongest between-group differences to
date observed in a group with dopamin-
ergic pathology (PD). The individual
characteristics (e.g., impulsivity, decision-
making and gambling-related behaviors)
linked to dopamine function in PG and
non-PG subjects also warrant consid-
eration from a clinical perspective and
suggest that these might represent novel
treatment targets that link particularly
closely to biological function [raising the
possibility that they may be particularly
amenable to targeting with medications
(Berlin et al., 2013)]. Additionally, other
potential endophenotypes like compulsiv-
ity (Fineberg et al., 2010, in press) warrant
consideration given their preliminary links
to treatment outcome in PG (Grant et al.,
2010). Additionally, systems that may reg-
ulate dopamine function warrant further
consideration in treatment development.
For example, in randomized clinical tri-
als, opioid antagonists like nalmefene and
naltrexone have been found to be superior
to placebo in treating PG (Grant et al.,
2006, 2008b), particularly amongst indi-
viduals with strong gambling urges or
familial histories of alcoholism (Grant
et al., 2008a). Similarly, glutamatergic sys-
tems warrant consideration in this regard
(Kalivas and Volkow, 2005), with pre-
liminary data linking the neutraceutical
n-acetyl cysteine to positive treatment
outcome in PG (Grant et al., 2007). As
dissecting the dopamine system is provid-
ing insight into PG, similar approaches
should be used to investigate serotonin
function in PG (Potenza et al., 2013), par-
ticularly given inconsistent findings with
serotonergic medications in the treatment
of PG (Bullock and Potenza, 2012). A
systematic approach to investigating the
neurobiology and clinical characteristics
of PG should help advance prevention and
treatment strategies for PG.
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